Schistosoma spp.: progress toward a defined vaccine.
During the last 2 decades, much was learned concerning the nature of acquired immunity in schistosomiasis, under experimental as well as field conditions. The knowledge is being applied now to design of a defined vaccine against this major parasitic disease. Several Schistosoma spp. antigens have been purified and shown to potentially protect in vivo. Determination of a method for presenting these antigens that will induce an optimal combination of cellular and humoral immune responses remains a critical step in vaccine development.
D000818:Animals; D000917:Antibody Formation; D000947:Antigens, Helminth / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D012547:Schistosoma / Q000276:immunology*; D012550:Schistosoma mansoni / Q000276:immunology; D012552:Schistosomiasis / Q000276:immunology / Q000517:prevention & control*; D012555:Schistosomiasis mansoni / Q000276:immunology / Q000517:prevention & control; D014612:Vaccines / Q000276:immunology*
D000947:Antigens, Helminth; D000954:Antigens, Surface; D014612:Vaccines